Summit Therapeutics is holding company. Through its subsidiaries, Co. is a biopharmaceutical company focused on the discovery, development, and commercialization of medicinal therapies. Co.'s ivonescimab is a bispecific antibody that combines the benefits of immunotherapy via a blockade of PD-1 with the anti-angiogenesis benefits of an anti-vascular endothelial growth factor into a single molecule. Co. also focuses on ridinilazole, its product candidate for treating patients suffering from Clostridioides difficile infection. Co.'s other product candidate, SMT-738, is in development for combating multidrug resistant infections, specifically carbapenem-resistant Enterobacteriaceae infections. The SMMT YTD return is shown above.
The YTD Return on the SMMT YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether SMMT YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the SMMT YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|